HS-130 / Scorpius Holdings - LARVOL DELTA

Kinematic Analysis of Gait Parameters in Patients Affected by Neuromyelitis Optica Spectrum Disorders: A Comparative Study (ECTRIMS 2024) - "However, no significant differences were found between groups in cadence (pwNMOSDs=121.80±10.54 vs. HS=130.28±9.35, p=0.082), gait cycle duration (pwNMOSDs=0.99±0.09 vs. HS=0.93±0.07, p=0.098), initial contact angle (ICA) (pwNMOSDs=25.33±6.05 vs. HS=27.83±3.34, p=0.288), toe-off angle (TOA) (pwNMOSDs=37.53±5.18 vs. HS=39.36±3.57, p=0.389), and step duration (pwNMOSDs=0.50±0.05 vs. HS=0.46±0.04, p=0.098)...This study provides objective insights into gait parameters affected in mild disability pwNMOSDs, revealing differences in gait speed, stride length, and total distance covered during the 2-minute walk test. Notably, the inclusion of pwNMOSD with low pyramidal scores suggests that observed differences between groups may be attributable to the cumulative impact of the disease. These findings hold clinical relevance for informing rehabilitation strategies tailored to the specific needs of this population."

Clinical • CNS Disorders • Fatigue • Immunology • Neuromyelitis Optica Spectrum Disorder • Pain • Rare Diseases

A Phase 1 Study of HS130 in Combination With Viagenpumatucel-L (HS110) in Patients With Solid Tumors (clinicaltrials.gov) - P1 | N=15 | Completed | Sponsor: Heat Biologics | Active, not recruiting ➔ Completed

Combination therapy • Trial completion • Immunology • Oncology • Solid Tumor

A Phase 1 Study of HS130 in Combination With Viagenpumatucel-L (HS110) in Patients With Solid Tumors (clinicaltrials.gov) - P1; N=15; Active, not recruiting; Sponsor: Heat Biologics; Recruiting ➔ Active, not recruiting; N=30 ➔ 15

Enrollment change • Enrollment closed • Immunology • Oncology • Solid Tumor

[VIRTUAL] Heat Biologics (BIO 2021) - "The Company has multiple product candidates in development leveraging the gp96 platform, including HS-110, which has completed enrollment in its Phase 2 trial, and a COVID-19 vaccine program in preclinical development. In addition, Heat Biologics is also developing a pipeline of proprietary immunomodulatory antibodies and cell-based therapies, including PTX-35 and HS-130 in Phase 1 clinical trials."

Immune Modulation • Infectious Disease • Inflammation • Novel Coronavirus Disease • Oncology

A Phase 1 Study of HS130 in Combination With Viagenpumatucel-L (HS110) in Patients With Solid Tumors (clinicaltrials.gov) - P1; N=30; Recruiting; Sponsor: Heat Biologics; Trial completion date: May 2021 ➔ Nov 2021; Trial primary completion date: Nov 2020 ➔ Jun 2021

Clinical • Combination therapy • Trial completion date • Trial primary completion date • Immunology • Oncology • Solid Tumor

"‣ Complete HS-130 Phase I trial – 1Q:21 ‣ Complete PTX-35 Phase I trial – 1Q:21 ‣ End of Phase II meeting for HS-110 – 1H:21" (@Hojo111111)

P1 data • P2 data

Heat Biologics Issued Key Patent on Combination Platform Therapy (Heat Biologics Press Release) - "Heat Biologics, Inc...announced it has been issued a patent (US Patent No. 10,758,611) by the U.S. Patent and Trademark Office (USPTO) covering compositions of matter that are part of Heat's gp96 platform in combination with a T cell costimulatory agonist in a single therapy. This newly issued US patent compliments Heat's growing patent estate on this platform technology, which also includes US Patent No. 10,046,047, with claims to compositions of matter covering Heat's gp96 platform in combination with OX40L, a T cell costimulatory agonist....'Our Phase 1 trials with gp96 (HS-110) in combination with OX40L (HS-130) and checkpoint inhibition are now underway, and we look forward to providing further clinical updates.'"

P1 data • Patent • Oncology

[VIRTUAL] A novel TNFRSF25 agonist, PTX35, synergizes with Gp96-Ig/OX40L-Ig to enhance effector and memory anti-tumor CD8+ T cell responses and delay tumor growth (AACR-II 2020) - "Preclinical results of mouse HS-130 (mHS-130) in combination with mouse HS-110 (mHS-110) has shown a potent anti-tumor effector and memory CD8+ T cell response, followed by tumor regression. We also assessed if PD-1 antagonist therapies further amplified our responses and found that checkpoint inhibition (CPI) synergizes effectively with PTX-35 and mHS-110. Therefore, the combinations of these treatments along with CPI may translate into an efficacious approach to treating human cancers."

Lung Adenocarcinoma • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Thoracic Cancer • CD8 • TNFRSF25

Newly added product (AccessWire) - P1, Oncology

Pipeline update